Associations between ACE-Inhibitors, Angiotensin Receptor Blockers, and Lean Body Mass in Community Dwelling Older Women
| Autor: | Betsy C. Wertheim, Sylvia Wassertheil-Smoller, Yann C. Klimentidis, Zhao Chen, Jennifer W. Bea, Candyce H. Kroenke, Andrea Z. LaCroix, Oleg Zaslavsky, Catherine R. Womack, Todd M. Manini, Cynthia A. Thomson |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Aging Demographics Article Subject Clinical Sciences 030204 cardiovascular system & hematology lcsh:Geriatrics Cardiovascular urologic and male genital diseases 03 medical and health sciences 0302 clinical medicine Threshold effect Bayesian multivariate linear regression Internal medicine Medicine 030212 general & internal medicine cardiovascular diseases Dual energy business.industry female genital diseases and pregnancy complications lcsh:RC952-954.6 Hypertension Lean body mass Public Health and Health Services Angiotensin Receptor Blockers Geriatrics and Gerontology business Research Article |
| Zdroj: | Bea, Jennifer W; Wassertheil-Smoller, Sylvia; Wertheim, Betsy C; Klimentidis, Yann; Chen, Zhao; Zaslavsky, Oleg; et al.(2018). Associations between ACE-Inhibitors, Angiotensin Receptor Blockers, and Lean Body Mass in Community Dwelling Older Women.. Journal of aging research, 2018, 8491092. doi: 10.1155/2018/8491092. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/0rq0n9s2 Journal of Aging Research, Vol 2018 (2018) Journal of Aging Research |
| DOI: | 10.1155/2018/8491092. |
| Popis: | Studies suggest that ACE-inhibitors (ACE-I) and angiotensin receptor blockers (ARBs) may preserve skeletal muscle with aging. We evaluated longitudinal differences in lean body mass (LBM) among women diagnosed with hypertension and classified as ACE-I/ARB users and nonusers among Women’s Health Initiative participants that received dual energy X-ray absorptiometry scans to estimate body composition (n=10,635) at baseline and at years 3 and 6 of follow-up. Of those, 2642 were treated for hypertension at baseline. Multivariate linear regression models, adjusted for relevant demographics, behaviors, and medications, assessed ACE-I/ARB use/nonuse and LBM associations at baseline, as well as change in LBM over 3 and 6 years. Although BMI did not differ by ACE-I/ARB use, LBM (%) was significantly higher in ACE-I/ARB users versus nonusers at baseline (52.2% versus 51.3%, resp., p=0.001). There was no association between ACE-I/ARB usage and change in LBM over time. Reasons for higher LBM with ACE-I/ARB use cross sectionally, but not longitundinally, are unclear and may reflect a threshold effect of these medications on LBM that is attenuated over time. Nevertheless, ACE-I/ARB use does not appear to negatively impact LBM in the long term. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|